$ETRA

TD Cowen initiated coverage on Electra (NASDAQ:ETRA) with a buy rating, highlighting the potential of its drug candidate ipsoprubart for treating secondary hemophagocytic lymphohistiocytosis. The company has a market cap of $585 million and has seen a 30% year-to-date decline. Analysts estimate $3.8 billion in sales by 2035, excluding upside from ELA822. Electra is preparing for an IPO, with significant investor demand.

OrbiMed Advisors disclosed an 11.0% stake in Electra Therapeutics (ETRA) following its IPO. The firm acquired the shares for investment, not control, and agreed to a 180-day lock-up period. OrbiMed is a healthcare-focused investment advisor.

GORDON CARL L purchased 1,333,333 indirectly-held shares of Electra Therapeutics, Inc. (ETRA) at $15.00 ($20.00M total) across 2 trades on 2026-09-21.

Electra Therapeutics (ETRA) reports that OrbiMed funds converted preferred shares into 5.55M common shares and purchased 1.33M additional shares at $15 each during its IPO on September 21, 2026. OrbiMed Advisors, a director and 10% owner, disclaims beneficial ownership except for pecuniary interest.

ORBIMED ADVISORS LLC purchased 1,333,333 indirectly-held shares of Electra Therapeutics, Inc. (ETRA) at $15.00 ($20.00M total) across 2 trades on 2026-09-21. Filed jointly with OrbiMed Capital GP VII LLC (Director) and OrbiMed Genesis GP LLC (Director).

Electra Therapeutics, Inc. (ETRA) reported insider trading activity. A Chief Technical Officer acquired 63,656 shares of common stock and Series A Convertible Preferred Stock on 09/21/2026, according to an SEC Form 4 filing.

Electra Therapeutics (ETRA) disclosed that director Nancy Stagliano converted 255,635 Series A Convertible Preferred Shares into Common Shares on a 1-for-1 basis following the company's IPO. The conversion was automatic and left her with 255,635 Common Shares.

Electra Therapeutics' CEO converted 455,484 Series A preferred shares into common stock, with 73,147 shares subject to future vesting. The conversion occurred on September 21, 2026, as part of the company's initial public offering. The preferred stock converted on a one-for-one basis with no expiration date.

Electra Therapeutics, Inc. (ETRA) filed an SEC Form 8-K — Other Events. Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. Amendment and Restatement of Certificate of Incorporation On September 21, 2026, in connection with the closing of the initial public offering (the “IPO”) of shares of common stock of Electra Ther

Electra Therapeutics (ETRA) began trading on Nasdaq on 18 September 2026, raising $350 million via an upsized IPO priced at $15.00 per share. HBM Healthcare Investments, which backed Electra with $30 million, now holds a 3.9% stake valued at $32.8 million. Electra's lead product, ipsoprubart, is in Phase 2/3 trials for sHLH and has received FDA and EMA designations.